These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1095 related items for PubMed ID: 25128520

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. The Effect of Reduced or Withdrawn Etanercept-methotrexate Therapy on Patient-reported Outcomes in Patients with Early Rheumatoid Arthritis.
    Wiland P, Dudler J, Veale D, Tahir H, Pedersen R, Bukowski J, Vlahos B, Williams T, Gaylord S, Kotak S.
    J Rheumatol; 2016 Jul; 43(7):1268-77. PubMed ID: 27252426
    [Abstract] [Full Text] [Related]

  • 3. Etanercept is effective as monotherapy or in combination with methotrexate in rheumatoid arthritis: subanalysis of an observational study.
    Gaubitz M, Göttl KH, Behmer O, Lippe R, Meng T, Löschmann PA.
    Clin Rheumatol; 2017 Sep; 36(9):1989-1996. PubMed ID: 28756532
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Predictors of remission with etanercept-methotrexate induction therapy and loss of remission with etanercept maintenance, reduction, or withdrawal in moderately active rheumatoid arthritis: results of the PRESERVE trial.
    Smolen JS, Szumski A, Koenig AS, Jones TV, Marshall L.
    Arthritis Res Ther; 2018 Jan 16; 20(1):8. PubMed ID: 29338762
    [Abstract] [Full Text] [Related]

  • 8. Discontinuation of etanercept after achievement of sustained remission in patients with rheumatoid arthritis who initially had moderate disease activity-results from the ENCOURAGE study, a prospective, international, multicenter randomized study.
    Yamanaka H, Nagaoka S, Lee SK, Bae SC, Kasama T, Kobayashi H, Nishioka Y, Ueki Y, Seto Y, Nishinarita M, Tamura N, Kimura N, Saito K, Tomita T, Nawata Y, Suzuki S, Ishigatsubo Y, Munakata Y, Makino Y, Inoue E, Tanaka Y, Takeuchi T, ENCOURAGE study group.
    Mod Rheumatol; 2016 Sep 16; 26(5):651-61. PubMed ID: 26698929
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Maintenance of remission with combination etanercept-DMARD therapy versus DMARDs alone in active rheumatoid arthritis: results of an international treat-to-target study conducted in regions with limited biologic access.
    Pavelka K, Akkoç N, Al-Maini M, Zerbini CAF, Karateev DE, Nasonov EL, Rahman MU, Pedersen R, Dinh A, Shen Q, Vasilescu R, Kotak S, Mahgoub E, Vlahos B.
    Rheumatol Int; 2017 Sep 16; 37(9):1469-1479. PubMed ID: 28597306
    [Abstract] [Full Text] [Related]

  • 12. Cost-effectiveness analysis of etanercept plus methotrexate vs triple therapy in treating Chinese rheumatoid arthritis patients.
    Shi ZC, Fei HP, Wang ZL.
    Medicine (Baltimore); 2020 Jan 16; 99(3):e16635. PubMed ID: 32011430
    [Abstract] [Full Text] [Related]

  • 13. Validation of the methotrexate-first strategy in patients with early, poor-prognosis rheumatoid arthritis: results from a two-year randomized, double-blind trial.
    O'Dell JR, Curtis JR, Mikuls TR, Cofield SS, Bridges SL, Ranganath VK, Moreland LW, TEAR Trial Investigators.
    Arthritis Rheum; 2013 Aug 16; 65(8):1985-94. PubMed ID: 23686414
    [Abstract] [Full Text] [Related]

  • 14. The Canadian methotrexate and etanercept outcome study: a randomised trial of discontinuing versus continuing methotrexate after 6 months of etanercept and methotrexate therapy in rheumatoid arthritis.
    Pope JE, Haraoui B, Thorne JC, Vieira A, Poulin-Costello M, Keystone EC.
    Ann Rheum Dis; 2014 Dec 16; 73(12):2144-51. PubMed ID: 23979914
    [Abstract] [Full Text] [Related]

  • 15. Two-year radiographic and clinical outcomes from the Canadian Methotrexate and Etanercept Outcome study in patients with rheumatoid arthritis.
    Keystone EC, Pope JE, Thorne JC, Poulin-Costello M, Phan-Chronis K, Vieira A, Haraoui B, CAMEO Investigators.
    Rheumatology (Oxford); 2016 Feb 16; 55(2):327-34. PubMed ID: 26361879
    [Abstract] [Full Text] [Related]

  • 16. Patients with moderate rheumatoid arthritis (RA) achieve better disease activity states with etanercept treatment than patients with severe RA.
    Keystone E, Freundlich B, Schiff M, Li J, Hooper M.
    J Rheumatol; 2009 Mar 16; 36(3):522-31. PubMed ID: 19228659
    [Abstract] [Full Text] [Related]

  • 17. Predictors of response to etanercept-methotrexate treatment: a post hoc logistic regression analysis of a randomized, open-label study in Latin American patients with rheumatoid arthritis.
    de la Vega M, Guerra Bautista G, Xavier RM, Pacheco-Tena C, Solano G, Pedersen RD, Szumski AE, Borlenghi C, Santana K, Vlahos B.
    Adv Rheumatol; 2021 Sep 08; 61(1):56. PubMed ID: 34496979
    [Abstract] [Full Text] [Related]

  • 18. Impact of flare on radiographic progression after etanercept continuation, tapering or withdrawal in patients with rheumatoid arthritis.
    Smolen JS, Pedersen R, Jones H, Mahgoub E, Marshall L.
    Rheumatology (Oxford); 2020 Jan 01; 59(1):153-164. PubMed ID: 31257453
    [Abstract] [Full Text] [Related]

  • 19. Long-term treatment response in rheumatoid arthritis patients starting adalimumab or etanercept with or without concomitant methotrexate.
    l'Ami MJ, Kneepkens EL, Nurmohamed MT, Krieckaert CLM, Visman IM, Wolbink GJ.
    Clin Exp Rheumatol; 2017 Jan 01; 35(3):431-437. PubMed ID: 28079512
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 55.